Explore how sponsors can recalibrate efficiency efforts to avoid overconcentrating trials at familiar sites and instead ...

In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven ...

BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...

In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & ...

Securing comparator drugs in the EU is a complex process shaped by availability constraints, regulatory expectations, and competitive market behavior. But if we have the right planning, strong ...

The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

So having a representative population is really important. One part of that is being able to enroll more patients in the ...

In today’s ACT Brief, we explore how site initiation can be leveraged to improve early trial performance through demonstrated ...

Explore early data from the ACTS program that reveal the volume and types of patient-reported barriers to cancer care and ...

In today’s ACT Brief, we examine persistent barriers limiting cancer trial participation and emerging approaches to address ...

By leveraging the Fresh Start Effect at site initiation and shifting from passive training to demonstrated readiness, ...

In a new ACT video interview, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American ...